Companies/Proteome Sciences Plc
Follow

Proteome Sciences Plc

London AIM (United Kingdom)

Proteome Sciences delivers content for precision medicine through services, biomarkers and reagents.
Go to market

Sector:
HEALTH CARE
Media
Showing 3 of 4
View all
www.proteomics.com
Current instruments
Type
Ticker
ISIN
SHARE
PRM
GB0003104196
London AIM United Kingdom (GB)
Top
News
PROTEOME SCIENCES PLC - Annual General Meeting
18 May 2023 - 01:00
PROTEOME SCIENCES PLC - Year End Results
20 Apr 2023 - 01:00
PROTEOME SCIENCES PLC - Interim Results
19 Aug 2022 - 08:21
PROTEOME SCIENCES PLC - Annual General Meeting
17 May 2022 - 09:10
Holding(s) in Company
01 Apr 2021 - 13:48
Investor Presentation
01 Apr 2021 - 10:34
Final Results
01 Apr 2021 - 08:40
Loan Amendment
30 Mar 2021 - 08:00
Trading Update and Notice of Results
26 Mar 2021 - 07:00
Year End Trading Update
25 Jan 2021 - 07:00
1 2 3
Show

10

Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
PRM
GB0003104196
London AIM
United Kingdom (GB)
Details of share in Proteome Sciences Plc with ticker PRM
Status
Active
Currency
GBP
Segment
AMSM
Listing
Sign in to buy
People
Mariola Söhngen
CEO
Christopher Pearce
Chairman of the board
Ian Pike
Board member
Richard Dennis
Board member
Ursula Ney
Board member
Roger McDowell
Board member
Martin Diggle
Board member
Company Details
Sector
HEALTH CARE
Website
Address
Coveham House, Downside Bridge Road, Cobham
Zip code
KT11 3EP
City/district
Surrey
Country
United Kingdom (GB)
Phones
Email
[email protected]
Registration number
02879724
LEI code
213800Q62ICXANKU2986
First trade date
03 Oct 1995
Company former names
Electrophoretics International Public Limited Company
15 Jun 1998
Timedbid Public Limited Company
13 Oct 1994
Registration date
10 Dec 1993
Short name
PRM

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More